UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

UC Davis Health and UCLA co-lead $16M study of AI use in breast cancer diagnosis

UC Davis Health and UCLA are co-leading a newly funded national clinical trial to evaluate whether AI can help radiologists interpret screening mammograms more accurately. The goal is to improve breast cancer detection and reduce unnecessary callbacks and anxiety for patients.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Mammograms may benefit women well into their 80s, UCLA study finds

For many older women, the question of whether to continue breast cancer screening has been uncertain. While most guidelines recommend mammograms up to age 74, advice for women 75 and older has been less clear.

September 26, 2025

Vol.51 No.35

Drugs & Targets

FDA approves Keytruda Qlex injection for subcutaneous use in 38 tumor indications

FDA approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) Sept. 19 for subcutaneous injection for adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab.

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.

September 19, 2025

Vol.51 No.34

In Brief

Caius Radu, Christine Mona, Amar Kishan, Beth Glenn, Mina Sedrak, William Lowry named program leaders at UCLA Health Jonsson CCC

Top row (left to right): Caius Radu, Amar Kishan and Christine Mona. Bottom row (left to right): Beth Glenn, Mina Sedrak and William Lowry. The UCLA Health Jonsson Comprehensive Cancer Center has appointed new leadership to several of its programs.

September 12, 2025

Vol.51 No.33

In Brief

Kai Tsao appointed system chief of solid tumor oncology at Northwell

Kai Tsao was named system chief of solid tumor oncology, at the Northwell Cancer Institute.

September 05, 2025

Vol.51 No.32

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

YOU MAY BE INTERESTED IN

UC Davis Health and UCLA co-lead $16M study of AI use in breast cancer diagnosis

Mammograms may benefit women well into their 80s, UCLA study finds

FDA approves Keytruda Qlex injection for subcutaneous use in 38 tumor indications

Rezatapopt monotherapy shows confirmed responses of eight solid tumor types in PYNNACLE phase II clinical trial

Caius Radu, Christine Mona, Amar Kishan, Beth Glenn, Mina Sedrak, William Lowry named program leaders at UCLA Health Jonsson CCC

Kai Tsao appointed system chief of solid tumor oncology at Northwell

Renew today!

Subscriber content

Never miss an issue!

Login